Written in Blood

This section features research from recent issues of Blood.

  • Uncovering the Natural History of Primary Ocular Adnexal MALT Lymphoma Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Primary ocular adnexal MALT lymphoma (POAML) is the most common orbital tumor affecting patients in the United States, but little is known about the natural history of the disease. In a report published in Blood, Amrita Desai, MD, from the Division of Hematology and Oncology at the Sylvester Comprehensive Cancer Center at the University of […]

  • Characterizing Ph-Like Acute Lymphocytic Leukemia: A High-Risk Subgroup With Few Treatment Options Tuesday, January 17th, 2017 | January Annual Meeting Edition 2017, Volume 3, Issue 2

    Treatment outcomes of patients with B-cell acute lymphocytic leukemia (B-ALL) vary according to age, with adult patients experiencing a poorer prognosis than pediatric patients. In a report published in Blood, Nitin Jain, MD, from the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, and authors examined the incidence and […]

  • In Utero Cytomegalovirus Infection Increases Risk of Developing Acute Lymphocytic Leukemia in Pediatric Patients Thursday, December 29th, 2016 | January 2017, Volume 3, Issue 1

    Children who had in utero cytomegalovirus (CMV) infection are more likely to develop childhood acute lymphocytic leukemia (ALL) than matched controls without infection, suggesting a role of infection in the etiology of ALL, according to the results of a next-generation sequencing (NGS) study published in Blood. The study authors, led by Stephen S. Francis, PhD, […]

  • Lestaurtinib Does Not Improve Survival for Patients With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia Thursday, December 29th, 2016 | January 2017, Volume 3, Issue 1

    Adding the FLT3 inhibitor lestaurtinib to standard firstline chemotherapy in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) does not improve survival rates, according to an analysis of data from two large, prospective, multicenter, phase III trials published in Blood by Steven Knapper, MD, from the Department of Hematology at the Cardiff University School […]

  • LYRIC Study: In the Age of Immunomodulatory Therapy, Do We Need New Lymphoma Response Criteria? Thursday, December 29th, 2016 | January 2017, Volume 3, Issue 1

    Since the first internationally accepted response criteria, the Lugano Classification Response Criteria, were published in 1999, advances in immunomodulatory therapies that affect imaging interpretation have resulted in the need for revised criteria for staging and response. To redefine response outcomes with use of immunomodulatory drugs, Bruce D. Cheson, MD, from the Georgetown University Hospital Lombardi […]

1 of 24
back to top